BCT BriaCell Therapeutics Corp.

3.255USD4.655 CAD · TSX-5.96%Mkt Cap: 28.43M USDP/E: —

BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against…

Institutional holders11 on file

Key Statistics

Company
Market Cap28.43M USD
Enterprise Value13.47M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-34.90M USD
Revenue/Share—
Last Price3.255 USD
Fiscal Year EndJul 2026
MR QuarterJul 2026
Employees31
CountryCA
SectorHealthcare
IndustryBiotechnology
ISINCA1079303071
Valuation
P/E (Trailing)—
P/E (Forward)-8.62
PEG—
EV/EBITDA-0.54
EV/Revenue—
P/S—
P/B1.76
EPS (TTM)-10.27 USD
EPS (Forward)-0.54 USD
52W Range
2.5737% of range12.59
52W High12.59 USD
52W Low2.573 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-212.82%
ROA-148.03%
ROIC—
ROCE-231.15%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-28.65M USD
CapEx (TTM)127.05K USD
FCF Margin—
FCF Yield-57.22%
Net Debt-20.54M USD
Net Debt/EBITDA0.57
Net Debt/FCF—
Balance Sheet
Debt/Equity—
Current Ratio2.76
Quick Ratio2.57
Book Value/Sh2.64 USD
Cash/Share2.35 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateJan 2, 2020
Splits
Last Split1:10
Split DateAug 25, 2025
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.8.73M
Float8.61M
Insiders0.14%
Institutions5.35%
Short Interest
Short Ratio2.9d
Short % Float0.14%
Short % Out.0.14%
Shares Short12.59K
Short (prev mo.)12.99K
Technical
SMA 503.642 (-10.6%)
SMA 2003.636 (-10.5%)
Beta1.66
S&P 52W Chg12.00%
Avg Vol (30d)4.40K
Avg Vol (10d)4.10K
Technical Indicators
RSI (14)44.3
MACD-0.0802
MACD Signal-0.0980
MACD Hist.+0.0179
BB Upper3.830 USD
BB Middle3.358 USD
BB Lower2.886 USD
BB Width28.11%
ATR (14)0.2148 USD
Vol Ratio (20d)1.24x

About BriaCell Therapeutics (TSE: BCT)

›

BriaCell Therapeutics (TSE: BCT) is listed on the Toronto Stock Exchange, where its shares trade in CAD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 31 employees.

The shares were at 4.655 CAD on 18 November 2026, down 59.2% over 52 weeks. Its 52-week range is 3.680 CAD to 18.00 CAD: the price is 74.1% below the high and 26.5% above the low.

Its market capitalisation is 40.65M CAD.

BriaCell Therapeutics reports return on equity of -212.8% and an operating margin of 0.0%.

It holds more cash than debt, a net cash position of 20.54M USD. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health.